L105 / HealZen Therap, Biopolar Hongye (Nantong) Pharma - LARVOL DELTA

L105, a next generation of Bcl-2 inhibitor, overcomes Bcl-2 mutation and exhibits superior antitumor activity (AACR 2023) - "L105 showed great potency on wild type and acquisition resistance mutations of Bcl-2, excellent oral bioavailability, and superior preclinical anti-tumor activities and safety profiles. It may provide new thoughts on treatment for a wide range of Bcl-2-dependent and Venetoclax-resistant hematological cancers."

IO biomarker • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • BCL2L1 • CASP3 • CYP2C9